Prevalence of Ocular Surface Complaints in Patients With Glaucoma Using Topical Intraocular Pressure-Lowering Medications

被引:263
|
作者
Fechtner, Robert D. [2 ]
Godfrey, David G. [3 ]
Budenz, Donald [4 ]
Stewart, Jeanette A. [1 ]
Stewart, William C. [1 ]
Jasek, Mark C. [5 ]
机构
[1] PRN Pharmaceut Res Network LLC, Dallas, TX 75240 USA
[2] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Ophthalmol, Newark, NJ 07103 USA
[3] Glaucoma Associates Texas, Dallas, TX USA
[4] Univ Miami, Bascom Palmer Eye Inst, Miami, FL USA
[5] Alcon Labs Inc, Ft Worth, TX 76101 USA
关键词
glaucoma; therapy; ocular surface disease; OSDI; prevalence; DRY EYE SYNDROME; OPHTHALMIC EMULSION; DISEASE; EFFICACY; MODERATE; SAFETY;
D O I
10.1097/ICO.0b013e3181c325b2
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine the prevalence of ocular surface disease (OSD) in patients with glaucoma using topical intraocular pressure (IOP) lowering therapy. Methods: This prospective observational study enrolled patients with primary open-angle glaucoma or ocular hypertension who were on a topical IOP-lowering medication regimen. Enrolled patients completed the ocular surface disease index (OSDI) and SDI scores (0-100, with 0 representing no symptoms) were calculated for each patient. Medical history, demographics, and concomitant medication information were also collected. Results: Overall, 630 patients from 10 sites participated. Of these, 305 patients (48.4%) had an OSDI score indicating either mild (n = 134, 21.3%), moderate (n = 84, 13.3%), or severe (n = 87, 13.8%) OSD symptoms. OSDI scores were significantly different between patients with and without a prior diagnosis of dry eye syndrome (25.2 +/- 15.4 vs 15.4 +/- 15.8, respectively; P = 0.0036) and between patients who did and did not use artificial tears at the time of study participation (23.0 +/- 15.6 vs 15.3 +/- 15.8, respectively; P = 0.0046). Mean OSDI scores varied significantly with the number of topical IOP-lowering medications used, with higher (more severe) OSDI scores in patients using multiple IOP-lowering medications. Specifically, patients on a single medication had a mean OSDI score of 12.9 +/- 13.1, which was significantly lower than those of patients on 2 (16.7 +/- 17.0; P = 0.007) or 3 medications (19.4 +/- 18.1; P = 0.0001). Conclusions: OSD is prevalent among medically treated patients with glaucoma. The severity of OSD symptoms is positively correlated to the number of IOP-lowering medications used.
引用
收藏
页码:618 / 621
页数:4
相关论文
共 50 条
  • [22] Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
    Tanihara, Hidenobu
    Kakuda, Takahiko
    Sano, Tetsuro
    Kanno, Takashi
    Kurihara, Yuji
    ADVANCES IN THERAPY, 2022, 39 (04) : 1659 - 1677
  • [23] Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months
    Hidenobu Tanihara
    Takahiko Kakuda
    Tetsuro Sano
    Takashi Kanno
    Yuji Kurihara
    Advances in Therapy, 2022, 39 : 1659 - 1677
  • [24] Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
    Wang, Kaidi
    Xu, Li
    Yuan, Zhilan
    Yao, Ke
    Zhao, Junmei
    Xu, Liang
    Fang, Aiwu
    Zhang, Mingzhi
    Wu, Lingling
    Ji, Jian
    Hou, Jiamin
    Liu, Qing
    Sun, Xinghuai
    BMC OPHTHALMOLOGY, 2014, 14
  • [25] A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma
    Noecker, RS
    Dirks, MS
    Choplin, NT
    Bernstein, P
    Batoosingh, AL
    Whitcup, SM
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2003, 135 (01) : 55 - 63
  • [26] Intraocular pressure-lowering efficacy and safety of bimatoprost 0.03% therapy for primary open-angle glaucoma and ocular hypertension patients in China
    Kaidi Wang
    Li Xu
    Zhilan Yuan
    Ke Yao
    Junmei Zhao
    Liang Xu
    Aiwu Fang
    Mingzhi Zhang
    Lingling Wu
    Jian Ji
    Jiamin Hou
    Qing Liu
    Xinghuai Sun
    BMC Ophthalmology, 14
  • [27] Efficacy and Safety of Intraocular Pressure-Lowering Agents Bimatoprost and Timolol Maleate in Glaucoma
    Chen, Lin
    Zeng, Xiaoli
    Huang, Xuewen
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2018, 14 (02) : 179 - 186
  • [28] Intraocular pressure-lowering and ocular exposure of NCX 1653, a novel nitric oxide-donating travoprost in models of ocular hypertension and glaucoma
    Impagnatiello, Francesco
    Storoni, Laura
    Brambilla, Stefania
    Masini, Emanuela
    Lanzi, Cecilia
    Toris, Carol B.
    Bergamini, Michael V. W.
    Ongini, Ennio
    Bastia, Elena
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [29] Topical and oral ketorolac administration increases the intraocular pressure-lowering effect of latanoprost
    Costagliola, Ciro
    Campa, Claudio
    Perri, Paolo
    Parmeggiani, Francesco
    Romano, Mario R.
    Incorvaia, Carlo
    CURRENT EYE RESEARCH, 2008, 33 (5-6) : 477 - 482
  • [30] Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension glaucoma or primary open-angle glaucoma
    Tamada, Y
    Taniguchi, T
    Murase, H
    Yamamoto, T
    Kitazawa, Y
    JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2001, 17 (01) : 19 - 25